I en pivotal randomiseret komparativ fase III- undersøgelse fik 2. 606 forsøgspersoner på over 60 år 0, 1 ml Idflu administreret intrakutant, og 1. 089 forsøgspersoner på over 60 år fik 0, 5 ml trivalent inaktiveret influenzavaccine administreret intramuskulær.
In a pivotal randomised comparative phase III trial, 2,606 subjects over 60 years of age received 0.1 ml of IDflu by intradermal route and 1,089 subjects over 60 years of age received 0.5 ml of a trivalent inactivated influenza vaccine administered by intramuscular route.